MXCT
MaxCyte IncKey Statistics
About MaxCyte Inc
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.
Fundamentals
| Revenue (TTM) | $33.03M |
| Gross Profit (TTM) | $26.80M |
| EBITDA | $-40.22M |
| Operating Margin | -94.80% |
| Return on Equity | -23.60% |
| Return on Assets | -12.60% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $1.61 |
| Price-to-Book | 0.55 |
| Price-to-Sales (TTM) | 2.84 |
| EV/Revenue | 0.261 |
| EV/EBITDA | -11.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -16.00% |
| Shares Outstanding | $106.86M |
| Float | $97.51M |
| % Insiders | 1.40% |
| % Institutions | 65.82% |
Historical Volatility
Volatility is currently contracting